Previous Close | 117.27 |
Open | 117.81 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 116.31 - 117.81 |
52 Week Range | 102.00 - 134.00 |
Volume | |
Avg. Volume | 7,116 |
Market Cap | 313.265B |
Beta (5Y Monthly) | 0.30 |
PE Ratio (TTM) | 31.92 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.19 (2.72%) |
Ex-Dividend Date | Apr 24, 2023 |
1y Target Est | N/A |
Q4 2022 Seres Therapeutics Inc Earnings Call
(Bloomberg) -- Nestlé SA has kicked off the sale of its peanut allergy medicine, people with knowledge of the matter said, as it seeks to reverse what’s proven to be a costly bet for the consumer company.Most Read from BloombergSorry, Twitter. Elon Found His Next Shiny Object.How to Get a Free Flight to Hong Kong in 500,000 Airline Ticket GiveawayWorld’s Rich Take Advantage as $1 Trillion Property Market CratersLightfoot Is First Chicago Mayor to Lose Reelection in 40 YearsMusk Was Right About T
BOCA RATON, Florida/LONDON (Reuters) -Major consumer companies including Kraft Heinz Co and Conagra Brands Inc are culling product lines to combat sky-high costs and falling consumer demand, their executives said this week. Many companies started slimming their offerings during the pandemic and are aggressively renewing those efforts, eliminating less-popular items to focus on products on which they can more easily raise prices amid prolonged inflation on food items. Executives at Nestle SA and Unilever Plc said they have seen billions in savings after ditching the laggards in their product portfolios.